Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.

Also called NCT01972724

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 114 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01972724
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01972724. Randomized; no masking; primary purpose treatment. Start 2013-12-16 (actual); primary completion 2016-10-17 (actual). Results posted on 2018-07-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy
Acronym
ADD
Condition
Type II Diabetes Mellitus
Intervention (Drug)
Pioglitazone
Intervention (Drug)
Metformin
Intervention (Drug)
Sulfonylurea
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct01972724
Content hash
7a04493337f34f4590f351b3f1e995c425282726d4226479113e9c7d2d3bb332